

ISSN 0924-977X
11 (Suppl. 3)
S91-S384

VOLUME 11

SUPPLEMENT 3

OCTOBER 2001

Abstracts of the
14th Congress of the
European College of
Neuropsychopharmacology

Istanbul, Turkey
October 13-17, 2001

ELSEVIER

EUROPEAN NEUROPSYCHOPHARMACOLOGY





3829.765350

VOL 11 SUPP 3

JCP ESTAR1

2/2



DOCUMENT SUPPLEMENT

14 FEB 2003

EUROPEAN NEUROPSYCHOPHARMACOLOGY

THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

EUROPEAN NEUROPSYCHOPHARMACOLOGY

THE JOURNAL OF THE EUROPEAN COLLEGE
OF NEUROPSYCHOPHARMACOLOGY

VOLUME 11 SUPPLEMENT 3 (2001)

Abstracts of the
14th Congress of the European College of
Neuropsychopharmacology

Istanbul, Turkey
October 13–17, 2001

BRITISH LIBRARY
DOCUMENT SUPPLY CENTRE
14 FEB 2003
CONFERENCE
INDEXED



ELSEVIER

VOLUME 11, SUPPLEMENT 3 (2001)

ELSEVIER SCIENCE B.V./ECNP

AMSTERDAM – LONDON – NEW YORK – OXFORD – PARIS – SHANNON – TOKYO

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Journal of the European College of Neuropsychopharmacology

Scope *European Neuropsychopharmacology* provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.

Editors-in-Chief

J.M. van Ree (Utrecht, The Netherlands)

S.A. Montgomery (London, UK)

Editorial Board

H. Akil (Ann Arbor, MI, USA)
A.C. Altamura (Milan, Italy)
F. Artigas (Barcelona, Spain)
I. Bitter (Budapest, Hungary)
P. Blier (Gainesville, FL, USA)
O. Civelli (Irvine, CA, USA)
G. Goodwin (Oxford, UK)
T. Higuchi (Kanagawa, Japan)
R.S. Kahn (Utrecht, The Netherlands)
J.M. Kane (Glen Oaks, NY, USA)
S. Kasper (Vienna, Austria)
C. Köhler (Sodertälje, Sweden)
G. Koob (La Jolla, CA, USA)
M.H. Lader (London, UK)

Y. Lecrubier (Paris, France)
P. Linkowski (Bruxelles, Belgium)
D. Marazziti (Pisa, Italy)
C.B. Nemeroff (Atlanta, GA, USA)
S.O. Ögren (Stockholm, Sweden)
A.J. Rush (Dallas, TX, USA)
A.F. Schatzberg (Stanford, CA, USA)
C.A. Tamminga (Baltimore, MD, USA)
J.W.G. Tiller (Parkville, Vic., Australia)
J.L. Waddington (Dublin, Ireland)
S. Yamawaki (Hiroshima, Japan)
J. Zohar (Ramat Gan, Israel)
E.E. Zvartau (St. Petersburg, Russia)

Types of paper Full-length *Research Papers*: detailing findings of original experimental or clinical research in any area of neuropsychopharmacology; *Short Communications*: brief research reports or results that have reached a stage where they are ready for preliminary communication; *Reviews* on specialised topics. *Letters to the Editor* relating to material published in the journal are also welcomed.

Submissions *Non-clinical* manuscripts and related editorial correspondence should be addressed to: ENP Secretariat, P.O. Box 85410, 3508 AK Utrecht, The Netherlands. *Clinical* manuscripts and related editorial correspondence should be addressed to: Professor Stuart A. Montgomery, European Neuropsychopharmacology, P.O. Box 8751, London W13 8WH, UK.

Advertising information. Advertising orders and enquiries can be sent to: **Europe and ROW:** Rachel Gresle-Farthing, Elsevier Science Ltd., Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843565; fax: (+44) (1865) 843976; e-mail: r.gresle-farthing@elsevier.co.uk. **USA and Canada:** Elsevier Science Inc., Mr Tino DeCarlo, 655 Avenue of the Americas, New York, NY 10010-5107, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: t.decarlo@elsevier.com. **Japan:** Elsevier Science Japan, Advertising Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan; phone: (+81) (3) 5561-5033; fax: (+81) (3) 5561 5047.

Publication information: *European Neuropsychopharmacology* (ISSN 0924-977X). For 2001, volume 11 is scheduled for publication. Subscription prices are available upon request from the Publisher or from the Regional Sales Office nearest you or from this journal's website (<http://www.elsevier.com/locate/euroneuro>). Further information is available on this journal and other Elsevier Science products through Elsevier's website (<http://www.elsevier.com>). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

Orders, claims, and product enquiries: please contact the Customer Support Department at the Regional Sales Office nearest you:

New York: Elsevier Science, PO Box 945, New York, NY 10159-0945, USA; phone: (+1) (212) 633 3730 [toll free number for North American customers: 1-888-4ES-INFO (437-4636)]; fax: (+1) (212) 633 3680; e-mail: usinfo-f@elsevier.com

Amsterdam: Elsevier Science, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) 20 4853757; fax: (+31) 20 4853432; e-mail: nlinfo-f@elsevier.com

Tokyo: Elsevier Science, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047; e-mail: info@elsevier.com

Singapore: Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192; phone: (+65) 434 3727; fax: (+65) 337 2230; e-mail: asiainfo@elsevier.com.sg

Rio de Janeiro: Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro - RJ, Brazil; phone: (+55) (21) 509 5340; fax: (+55) (21) 507 1991; e-mail: elsevier@campus.com.br [Note (Latin America): for orders, claims and help desk information, please contact the Regional Sales Office in New York as listed above]

© 2001 Elsevier Science B.V./ECNP. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Science B.V./ECNP, and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Global Rights directly through Elsevier's home page (<http://www.elsevier.nl>), by selecting 'Obtaining Permissions'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) 978 7508400, fax: (+1) 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 171 631 5555; fax: (+44) 171 631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

∞ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

supersensitivity mania, rendering Lithium treatment more and more ineffective (H. Himmelhorth, in J.C. Soares & S. Gershon, 2000). Furthermore, prior polypharmaceutical course of treatment, especially antidepressants, contributes to Lithium resistance. Withdrawal rebound can make Lithium ineffective or counterproductive. Finally: "treatment with Lithium for less than two years is either of negligible benefit or of actual harm to bipolar patients. A too short term treatment may be worse than useless. Three years is probably the minimum length" (G.M. Goodwin, 1994). Therefore, the prescription of Lithium in acute mood episodes is warranted. This decision must nonetheless be well thought over, taking into account a long-term strategy with the perspective of prolonged Lithium treatment, principally to stabilize mood oscillations, prevent or counteract ongoing cerebral damage, and prevent suicide.

Indeed, on the long term, Lithium has many beneficial effects: against suicidal behaviour, viral infection, and more interestingly, against neurodegeneration (H.K. Manji *et al.*, 2000). The treatment's perspective is thereby broadened to neuroprotection, neurogenesis, and management of pathological brain aging.

There are several other drugs used to treat mania, with a more rapid efficacy. These can represent an alternative choice. Again, the decision to use Lithium, alone or combined with other drugs in acute mood episodes, must take into account a long-term strategy and the long-term beneficial effects.

References

- [1] Cade J.F.J.: Lithium salts in the treatment of psychotic excitement. *Med. J. Aust.*, 36: 349-352, 1949.
- [2] El-Mallakh R.S.: Lithium: Actions and mechanisms, 1 vol., American Psychiatric Press, London, 1996.
- [3] Goodwin F.K., Jamison K.R.: Manic-depressive illness. Oxford University Press, New York, NY, 1990.
- [4] Goodwin G.M.: The recurrence of mania after lithium withdrawal: implications for the use of lithium in the treatment of bipolar affective disorder. *Br. J. Psychiatr.*, 164: 146-152, 1994.
- [5] Manji H.K., Bowden CL, Belmaker R H.: Bipolar medications, 1 vol., American Psychiatric Press, 2000.
- [6] Soares J.C., Gershon S: Bipolar disorders: Basic mechanism and therapeutic implications, Marcel Dekker, inc. New York: Basel.
- [7] Vieta E., Gasto C.: Trastornos bipolares. 1 vol., Springer Verlag Iberica, Barcelona, 1997.

S.13.03 Typical and atypical antipsychotics in the treatment of mania

G.M. Goodwin. *University Department of Psychiatry, The Warneford Hospital, Oxford OX3 7JX, UK*

For many years, antipsychotics have been the cornerstone of treatment for acute mania in Europe. It provoked surprise, and not a little consternation, therefore, that in influential US guidelines, antipsychotics were defined to be *adjunctive*, not first line, in the management of mania. The first line drugs were declared to be mood stabilisers (1). The term mood stabilizer is imprecisely defined but carries a reassuring ring. It is bestowed on lithium for the good reason that there exists clear evidence that it prevents recurrence and relapse in the long term. The term is conferred upon the anticonvulsants on the basis of much less convincing evidence. Although divalproex certainly has equal efficacy to lithium in the treatment of acute mania (2), in long term maintenance the results were inconclusive (3).

The basis for the distinction between mood stabilisers and adjunctive treatments was always opinion, rather than evidence. There is an excellent controlled comparison of the gold standard

mood stabiliser, lithium with the original antipsychotic, chlorpromazine, which showed an advantage to chlorpromazine in highly active manic patients (4). This data accords with clinical experience and indeed with audits of clinical practice internationally, which all illustrate the widespread, perhaps universal use of antipsychotic drugs, often at quite high doses. Severe mania may demand the actions that only antipsychotics can produce.

A greater challenge comes from the development of the atypical antipsychotics and the realisation that lower doses of the classical drugs are preferable in the treatment of schizophrenia because of the severity of adverse effects. We remain a little uncertain whether the central action that is sought in acute treatment of mania is primarily the chemical straightjacket of antipsychotic overdose. The classical antipsychotics certainly reduce demands on staff (4) by controlling behaviour. The atypical antipsychotics will not have the same side effect burden. Will they prove to be as useful as the older drugs? How we balance the interests of staff and patients, suggests the need for new approaches to assessing outcome in treatment trials, and more emphasis on the patient experience.

The new trials we already have are interesting because they suggest that atypicals can produce antimanic effects that are certainly superior to placebo and probably additive to the action of so-called mood stabilisers like divalproex and lithium. This is already suggested by studies of risperidone and olanzapine. Indeed combination treatments are extremely common in practice and may allow the balance between efficacy and side effects to be optimised in acute and long term treatment.

There is the further issue of whether atypical antipsychotics are themselves 'mood stabilising', and whether the meaning of that term is in need of re-statement. Certainly clozapine has a reputation and some evidence to support a potent action in the rapid cycling states where mood instability is a defining feature.

We are at a stage of rapid and incremental growth in available information because of the efforts of companies to identify the actions of their still new compounds. The greater challenge is to integrate the increasingly wide range of choices into coherent clinical planning and humane treatment of a difficult condition. These are challenges primarily for clinicians, not for industry, and can only be addressed by the growth of the trial culture within everyday practice.

References

- [1] Frances, A., Docherty, J.P. and Kahu, D.A. The Expert Consensus Guideline series: treatment of bipolar disorder. 1996 *J. Clin. Psychiatr.* 57 (Suppl 12A), 1-88.
- [2] Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. 1994 *Journal of the American Medical Association*, 271: 918-924.
- [3] Bowden CL, Calabrese, JR, McElroy, SL, et al. A randomised, placebo-controlled 12-month trial of Divalproex and lithium in treatments of outpatients with bipolar I disorder. 2000 *Arch. Gen. Psychiatry* 57, 481-489
- [4] Prien-RF, Caffey-EM Jr, Klett-CJ Comparison of lithium carbonate and chlorpromazine in the treatment of mania. 1972, *Arch Gen Psychiatry*. 26: 146-153

S.13.05 Treatment of mixed episodes

G.S. Sachs. *Harvard Bipolar Research Program, USA*

Mixed episodes challenge clinicians and researchers to assess and treat a condition defined by frequent fluctuation of signs and symptoms. Terms such as Bipolar Disorder and Manic-Depressive